Figure 7.

In vivo combination therapy of PKN3 siRNA and DXR for lung MCF-7-(A and B) and LLC-metastasized mice (C and D). (A-D) DXR, followed by PKN3 siRNA was administered to mice on day 5 subsequent to inoculation, and PKN3 siRNA was administered on days 7, 9 and 11. The mice were sacrificed at day 13 after inoculation, and then the excised livers were weighed. In (A and B), each result represents the mean + standard deviation (n=4-5). In (C and D), each result represents the mean ± standard deviation (n=3-5). *P<0.05, **P<0.01. PKN3, protein kinase N3; siRNA, small interfering RNA; DXR, doxorubicin.